Zobrazeno 1 - 10
of 307
pro vyhledávání: '"As, Dobrodeev"'
Autor:
A. Yu. Dobrodeev, D. N. Kostromitsky, A. S. Tarasova, S. G. Afanasyev, N. N. Babyshkina, A. A. Ponomaryeva, I. V. Larionova, T. A. Dronova, D. I. Azovsky
Publikováno v:
Сибирский онкологический журнал, Vol 23, Iss 1, Pp 162-169 (2024)
Background. Colorectal cancer is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Population-based studies have shown that 25–30 % of patients with colorectal cancer have synchronous liver metastases a
Externí odkaz:
https://doaj.org/article/0187498671064e6ebd6f2a4e56f69345
Autor:
S. Yu. Dobner, S. V. Fedosenko, A. Yu. Dobrodeev, N. D. Yarovoy, E. N. Samtsov, А. V. Dubakov, E. A. Starovoitova, О. A. Denisova, N. A. Kirillova
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 5, Pp 49-59 (2023)
The purpose of the study was to compare the efficacy of regular prolonged inhalation therapy with tiotropium bromide delivered via the Respimat inhaler and short-acting bronchodilator (SAB) therapy with ipratropium bromide/fenoterol in the perioperat
Externí odkaz:
https://doaj.org/article/c104d8e309f949e1a49491430e531617
Autor:
Nataliya Babyshkina, Nataliya Popova, Evgeny Grigoryev, Tatyana Dronova, Polina Gervas, Alexey Dobrodeev, Dmitry Kostromitskiy, Victor Goldberg, Sergei Afanasiev, Nadejda Cherdyntseva
Publikováno v:
Drug Target Insights, Vol 18, Iss 1 (2024)
Immunotherapy has become an integral part of a comprehensive treatment approach to metastatic colorectal cancer (mCRC). Nivolumab (Opdivo) is a human immunoglobulin G4 monoclonal antibody that blocks the interaction between the programmed cell death
Externí odkaz:
https://doaj.org/article/3a8b6f17462045d08f866d5fe967bc4f
Autor:
A. Yu. Dobrodeev, D. N. Kostromitsky, S. G. Afanasyev, A. S. Tarasova, N. N. Babyshkina, A. A. Ponomareva
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 2, Pp 160-167 (2023)
Background. Colorectal cancer (CRC) is one of the most common cancers and one of the most leading causes of cancer-related deaths worldwide. Approximately 35 % of CRC patients have liver metastases at the time of diagnosis. These patients have a poor
Externí odkaz:
https://doaj.org/article/fd868728ae044b60b2daf3e9a5ef3ab1
Autor:
A. Yu. Dobrodeev, D. N. Kostromitsky, A. S. Tarasova, S. G. Afanasyev, N. N. Babyshkina, A. A. Ponomaryeva, R. V. Ermolenko, I. G. Frolova, O. V. Cheremisina
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 6, Pp 17-24 (2023)
The purpose of the study was to assess the short-term effcacy and tolerability of neoadjuvant chemotherapy (NAC) in colorectal cancer (CRC) patients with isolated liver metastasis.Material and Methods. Since 2020, a pilot study including 23 CRC patie
Externí odkaz:
https://doaj.org/article/efd9630d7f6f4c30b2eb184d1b6857f1
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 5, Pp 102-108 (2022)
Purpose of the study: to investigate the composition of the intestinal microbiota and determine the feasibility of using it in diagnosis and prognosis of colorectal cancer (CRC). Material and methods. The study included 75 patients with CC (study gro
Externí odkaz:
https://doaj.org/article/4102c20258594705a8c7bbc468a483c5
Autor:
N. N. Babyshkina, T. A. Dronova, P. A. Gervas, N. O. Popova, A. Yu. Dobrodeev, D. N. Kostromitsky, S. G. Afanasyev, V. E. Goldberg, N. V. Cherdyntseva
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 5, Pp 135-141 (2022)
Aim of the study: a systematic analysis of the modern literature data on the nivolumab monotherapy efficacy in patients with metastatic colorectal cancer (mCRC). Material and methods. The review summarizes the results of clinical studies of the nivol
Externí odkaz:
https://doaj.org/article/ca5c29b526c3451c841f14c920c0df20
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Ocean Engineering 15 December 2022 266 Part 5
Autor:
A. V. Avgustinovich, S. G. Afanasyev, A. Yu. Dobrodeev, M. Yu. Volkov, D. N. Kostromitsky, L. V. Spirina, O. V. Cheremisina
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 1, Pp 11-19 (2022)
Background. Currently, perioperative chemotherapy is the standard treatment option for resectable gastric cancer (GC ) at stages higher than T1. Preoperative chemotherapy was shown do not adversely affect the course of the postoperative period in gas
Externí odkaz:
https://doaj.org/article/c0b54ca61dc54a4a95f2ed0d4e0fd68d